Fracture Prevention Clinical Studies
Our clinical studies group participates in multicentre international
clinical trials evaluating potential osteoporosis treatments that are
in the final stages of pharmaceutical development. We recruit patients
and volunteers who have had a fracture or who have a family history of
osteoporosis. Volunteer participants who meet specific risk criteria
are randomly allocated to receive a new drug or various combinations of
drugs.
Staff
Dr Vivienne Milch |
Dr Yvonne Selecki |
| Clinical Research Associate Maureen Gaynor |
News
Study shows that prostate cancer increases the risk of bone fracture
MEDIA RELEASE:
14 May 2008
As unlikely as it sounds, scientists at Garvan have shown that there is a link between prostate cancer and a higher risk of bone fracture. Their study suggests that men with prostate cancer face a 50% higher risk of fracture, which increases to nearly 100% if they are receiving androgen deprivation therapy for their prostate cancer.
Genotyping takes us closer to an osteoporosis fingerprint
MEDIA RELEASE:
30 Apr 2008
Garvan collaborated with the Icelandic genetics company, deCode, in an extensive multi-nation genome-wide search to find the genes linked to osteoporosis and fracture. Five regions of interest have been identified that appear to warrant further scientific investigation.
Low testosterone in men doubles their risk of bone fracture
MEDIA RELEASE:
15 Jan 2008
Garvan researchers have shown that low levels of testosterone in men double their risk of bone fracture, all other risk factors being equal. This is a significant finding given that 30% of the 110,000 osteoporotic fractures experienced in Australia each year occur in men. It is likely that the findings will have implications for clinical practice, possibly including testosterone supplementation.
